-
Real-World Healthcare Resource Utilization Patterns Among Patients With Non-Small Cell Lung Cancer Treated With Amivantamab Monotherapy
Mar 10, 2025, 14:00 PM -
Autism Spectrum Disorder Caregiver Healthcare Resource Utilization and Economic Burden: Results From the 2024 US National Health and Wellness Survey
Mar 10, 2025, 14:00 PM -
Informal Caregivers' Attitudes Towards Robots in Hungary and Poland
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of First-Line Tremelimumab Plus Durvalumab Versus Sorafenib in Unresectable Hepatocellular Carcinoma
Mar 10, 2025, 14:00 PM -
Real-World Temporal and Indication-Specific Variation in Drivers of GLP-1 RA Discontinuation
Mar 10, 2025, 14:00 PM -
The Impact of Prior Choice for Between-Study Heterogeneity in Network Meta-Analysis on Model Conclusions
Mar 10, 2025, 14:00 PM -
Characterizing the Burden and Drivers of Healthcare Utilization and Spending for Epilepsy and Seizures in the U.S., 2016-2022
Mar 10, 2025, 14:00 PM -
Impact of COVID-19 on Quality of Life and Work Productivity Among Symptomatic US Adults Testing Positive for SARS-CoV-2: Interim Analysis of a Nationwide Longitudinal Study
Mar 10, 2025, 14:00 PM -
Use of Clinical Outcome Assessments in Specialty Drug Coverage Policies
Mar 10, 2025, 14:00 PM -
Relationships Between ICER Clinical Evidence Ratings and FDA Approval Decisions
Mar 10, 2025, 14:00 PM -
Patient's Experience of Ulcerative Colitis: A Conceptual Model Based on Qualitative Interviews
Mar 10, 2025, 14:00 PM -
A Comprehensive Review of Real-World Evidence (RWE) Use in Submissions to Canada's Drug Agency (CDA)
Mar 10, 2025, 14:00 PM -
Systematic Review of Secondary Primary Malignancies (SPMs) in Patients Treated with Chimeric Antigen Receptor T-cell (CAR-T) Therapies
Mar 10, 2025, 14:00 PM -
Addressing Neighborhood-Level Opioid Data Gaps: Development of an Interactive Dashboard for Prescription Trends and Buprenorphine Access in California
Mar 10, 2025, 14:00 PM -
Use of Artificial Intelligence for Rapid Epidemiology Reviews With Pooled Prevalence and Incidence Estimates
Mar 10, 2025, 14:00 PM -
Cost-per-Event Analysis of Risankizumab in Comparison to Ustekinumab for the Treatment of Patients With Moderate-to-Severe Crohn’s Disease in Brazil
Mar 10, 2025, 14:00 PM -
Predicted Effectiveness of First- and Second-Line Treatment Sequences in Advanced or Recurrent Endometrial Cancer
Mar 10, 2025, 14:00 PM -
Revisiting Archetypes: New Archetypes for Strategic Global Value Evidence Planning
Mar 10, 2025, 14:00 PM -
Disparities in COVID-19 Vaccination Uptake by Social Vulnerability Index: A US nationwide study
Mar 10, 2025, 14:00 PM -
From Bias to Confidence: Exploring Quantitative Bias Analysis’ (QBA’s) Role in Matching Adjusted Indirect Treatment Comparison
Mar 10, 2025, 14:00 PM